Lipoxen to test pharma candidates with Russia's Pharmsynthez
This article was originally published in Scrip
Executive Summary
Lipoxen has signed an agreement with Pharmsynthez, a private Russian research-based company, which will allow Pharmsynthez to apply Lipoxen's ImuXen and PolyXen technologies to six drug and vaccine candidates. Pharmsynthez will also fund clinical proof of concept trials which are planned to be completed by the end of next year.
You may also be interested in...
Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A
Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.